Maxim Group analyst Jason McCarthy maintained a Buy rating on Athersys (NASDAQ: ATHX) today and set a price target of $6. The company’s shares closed yesterday at $2.10.
McCarthy observed:
“Athersys reported 1Q18 with a net loss of $10.1M and ended the period with $50M in cash. Cash excludes the $10M in escrow associated with the expanded partnership with Helios..”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.9% and a 36.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.63 and a one-year low of $1.29. Currently, Athersys has an average volume of 583.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
